Park Square is pleased to announce the placement of Srinivas (Sri) Chunduru, Ph.D. as Chief Scientific Officer at EveryONE Medicines, biotechnology company heralding a new era in medicine by building a platform for the rapid development of individualized precision nucleic acid therapeutics for ultra-rare diseases at scale. The company is backed by leading investors including Khosla Ventures, Third Rock Ventures, and GV.
Chunduru most recently served as Vice President, Translational Research at Idera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases. Over the course of his career, Chunduru has worked in both early-stage and established companies alike, leading biology and the discovery and development of novel therapeutics to treat significant unmet medical needs. He previously held roles of increasing responsibility at Tetralogic Pharmaceuticals, Gentara, and ViroPharma.
Chunduru received his Ph.D. in Biochemistry from The University of Akron and a B.Sc. in Biology from Osmania University.